ESC Congress 2024 — MRAs reduce the risk of cardiovascular events in patients with HF, HFpEF and HFrEF.

Prof Pardeep Jhund (University of Glasgow, UK) joins us to discuss findings from a study investigating mineralocorticoid receptor antagonists (MRAs) across different types of heart failure.

This pre-specified, patient-level meta-analysis of RALES (spironolactone), EMPHASIS-HF (eplerenone), TOPCAT (spironolactone) and FINEARTS-HF (fineronone) enrolled 13,846 patients with HFrEF, HmrEF and HFpEF to evaluate the effect of MRAs on the outcomes of cardiovascular death or heart failure hospitalisation.

MRAs were found to reduce the risk of cardiovascular death or HF hospitalisation, with these effects consistent across all subgroups in the HFrEF and HFmrEF and HFpEF trials.

Interview Questions:
1. What is the importance of this analysis?
2. What was design and the cohort of the study?
3. What are your key findings?
4. What are the take-home messages for practice?
5. What further research is required?

Recorded on-site at ESC Congress 2024, London.  

Editors: Jordan Rance and Mirjam Boros. 
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.  

Support: This is an independent interview produced by Radcliffe Cardiology.